Related Experiment Video

Updated: Sep 26, 2025

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.4K

Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple Myeloma

Stephanie Kadow1, Fabian Schumacher2, Melanie Kramer1

  • 1Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.

Cancers
|April 23, 2022
PubMed

Insights

New research identifies mitochondrial Kv1.3 channels as a promising target for multiple myeloma treatment. Inhibiting these channels effectively kills myeloma cells while sparing healthy ones, offering hope for a cure.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Multiple myeloma treatments are palliative, with all patients eventually relapsing.
  • Novel therapies are needed for potential cure and improved survival.

Purpose of the Study:

  • To investigate mitochondrial Kv1.3 channels as a therapeutic target in multiple myeloma.
  • To evaluate the efficacy and resistance mechanisms of mitochondrial Kv1.3 inhibitors.

Main Methods:

  • Assessed Kv1.3 expression in multiple myeloma cells.
  • Tested mitochondrial Kv1.3 inhibitors (PAPTP, PCARBTP) on myeloma cell lines and patient samples.
  • Investigated apoptosis pathways and multidrug resistance (MDR-1) involvement.
  • Evaluated combination therapy with ABT-199 (venetoclax).

Main Results:

  • Multiple myeloma cells express mitochondrial Kv1.3.
  • PAPTP and PCARBTP effectively killed myeloma cells, sparing healthy bone marrow cells.
  • Cell death occurred via mitochondrial apoptosis.
  • MDR-1 up-regulation was identified as a resistance mechanism.
  • Combination with ABT-199 showed synergistic effects, particularly in t(11;14) negative myeloma.

Conclusions:

  • Mitochondrial Kv1.3 channels are druggable targets for multiple myeloma.
  • Mitochondrial Kv1.3 inhibitors show potential as a novel therapeutic strategy.
  • Combination therapy with venetoclax may overcome resistance in certain myeloma subtypes.
Keywords:
ABT-199Kv1.3mitochondriamultiple myelomavenetoclax

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
479
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.3K
Ion Channels01:19

Ion Channels

The movement of ions like sodium, potassium, and calcium into and out of the cell is essential to maintain the electrochemical gradient in living cells. The ion channels—a class of membrane transport proteins—help maintain this ionic gradient for the smooth functioning of physiological activities such as maintaining cell size and volume, conducting nerve impulses, and gas and nutrient exchange.
Ion channels are specialized integral membrane proteins on the plasma membrane that allow...
88.5K
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
8.7K